Written and maintained by CASRAI Editorial Board
Last updated
Informational only; this medical device and clinical informatics reference summarizes FDA 510(k) clearances, ambulatory electrocardiography (ECG) architectures, and CMS/CPT coding rules and does not provide individual medical advice or clinical placement instructions.
Preventice Solutions (acquired by Boston Scientific in 2021 and operated as Boston Scientific Cardiac Diagnostic Technologies, Inc.) is an ambulatory cardiac diagnostics developer and Medicare-enrolled Independent Diagnostic Testing Facility (IDTF) best known for the FDA 510(k)-cleared BodyGuardian family of wearable remote ECG monitors (including BodyGuardian MINI, BodyGuardian Heart, and the BodyGuardian Remote Monitoring System). Along with peer platforms—BioTelemetry (Mobile Cardiac Outpatient Telemetry [MCOT] and ePatch, acquired by Royal Philips), Bardy Diagnostics (Carnation Ambulatory Monitor [CAM] P-wave patch, acquired by Hillrom/Baxter), and AccurKardia (AccurECG device-agnostic Software as a Medical Device [SaMD])—Preventice Solutions forms the core technical infrastructure for outpatient arrhythmia detection, cryptogenic stroke workups, and decentralized cardiovascular clinical trials.
What Is Preventice Solutions?
Originally founded in collaboration with Mayo Clinic cardiology investigators, Preventice Solutions engineered the BodyGuardian platform to consolidate four distinct ambulatory ECG monitoring modalities—short-term Holter (24–48 hours), Extended Holter (up to 14–30 days), patient-activated Cardiac Event Monitoring (CEM), and real-time Mobile Cardiac Telemetry (MCT)—into a single, waterproof wearable patch/sensor architecture.
Under FDA 21 CFR Part 870 regulations, BodyGuardian hardware and cloud analytics operate across two primary classification categories:
- 21 CFR § 870.2800 (Medical Magnetic Tape Recorder — Product Code DSH, Class II): Covers continuous ambulatory Holter and extended-wear ECG recording where stored waveform data are analyzed retrospectively or at intermediate intervals.
- 21 CFR § 870.1025 (Arrhythmia Detector and Alarm — Product Code DSI, Class II): Covers Mobile Cardiac Telemetry (MCT) systems (cleared under FDA 510(k) notifications including
K121197,K192732, andK243349) that continuously analyze beat-to-beat ECG signals, detect physiological arrhythmias (such as atrial fibrillation, pause, bradycardia, supraventricular tachycardia, and ventricular tachycardia), and transmit near-real-time telemetry via a Bluetooth-paired cellular gateway to certified cardiac technicians at a 24/7 IDTF.
Comparing Preventice Solutions, BioTelemetry, Bardy Diagnostics, and AccurKardia
When cardiology departments, electrophysiology clinics, and clinical trial sponsors select an ambulatory ECG vendor—or compare multi-modality telemetry systems against single-modality extended Holter patches like the Zio patch—they evaluate four architectural dimensions: hardware form factor, signal acquisition focus, real-time cellular telemetry vs. post-wear download, and SaMD algorithm openness.
| Platform & Corporate Parent | Flagship FDA 510(k)-Cleared System | Primary Signal & Telemetry Architecture | Target Clinical & Research Use Cases |
|---|---|---|---|
| Preventice Solutions (Boston Scientific) | BodyGuardian MINI / BodyGuardian Heart (e.g., K192732, K243349) |
Waterproof wearable sensor detachable onto replaceable adhesive strip or lead-wire adapter; pairs with dedicated cellular handset to switch remotely between Holter, Extended Holter, Event, and continuous MCT without swapping hardware. | Multi-modality outpatient arrhythmia workflows, post-ablation surveillance, and clinical trials requiring remote modality step-up or real-time safety alerts. |
| BioTelemetry (Royal Philips) | Philips MCOT (Mobile Cardiac Outpatient Telemetry) & ePatch | Dual-channel continuous cellular telemetry sensor (MCOT) and multi-channel extended-wear patch (ePatch) integrated with Philips Cardiologs deep-learning cloud ECG analysis and IDTF technician triage. | High-acuity outpatient arrhythmia monitoring, syncope evaluation, and cryptogenic stroke atrial fibrillation detection requiring dual-lead morphology. |
| Bardy Diagnostics (Hillrom / Baxter) | Carnation Ambulatory Monitor (CAM) Patch | Single-piece, narrow hourglass-shaped extended Holter patch positioned directly vertically along the sternum to maximize low-amplitude, low-frequency atrial P-wave dipole capture. | Differentiating narrow-complex supraventricular arrhythmias (atrial tachycardia, atrial flutter, AVNRT, and atrial fibrillation) where standard chest vectors obscure the P-wave. |
| AccurKardia (Independent SaMD) | AccurECG (FDA 510(k) K231436, Class II SaMD) |
Hardware-agnostic cloud/API Software as a Medical Device (SaMD) that ingests raw ECG strips from third-party Holter, Event, and MCT hardware for automated beat-by-beat classification across 13 arrhythmia categories. | IDTFs, OEM patch manufacturers, and core ECG laboratories seeking a standardized, device-independent AI interpretation pipeline. |
Deep Dive into Peer Platforms: BioTelemetry, Bardy Diagnostics, and AccurKardia
BioTelemetry (Philips Ambulatory Cardiac Diagnostics)
BioTelemetry, Inc. (formerly CardioNet, acquired by Royal Philips in 2021) established the clinical category of Mobile Cardiac Outpatient Telemetry (MCOT). Unlike traditional patient-triggered event monitors that rely on a symptomatic patient pressing a record button, or passive extended Holter patches that store ECG waveforms on flash memory until the patient mails the device back at day 14, BioTelemetry’s MCOT sensor continuously streams ECG data to a paired cellular monitor. On-board and cloud algorithms (including the FDA-cleared Cardiologs deep neural network) flag asymptomatic and symptomatic rhythm disturbances in near real time for review by certified rhythm analysis technicians at a Medicare-enrolled IDTF operating under 42 CFR § 410.33.
Bardy Diagnostics (Carnation Ambulatory Monitor — CAM Patch)
Bardy Diagnostics (acquired by Hillrom and subsequently Baxter International) addressed a specific electrophysiological limitation of conventional lead-less chest patches: traditional short-axis patches placed over the left pectoral region prioritize large-amplitude ventricular QRS complexes, often leaving the low-amplitude, low-frequency atrial P-wave buried in baseline noise. The FDA 510(k)-cleared CAM patch uses a patented sternal vector placement aligned with the natural electrical axis of atrial depolarization during sinus rhythm. By preserving P-wave morphology and PR-interval visibility up to 14 days, the CAM patch assists electrophysiologists and clinical trial adjudication committees in distinguishing true atrial fibrillation from ectopic atrial tachycardia, atrial flutter with variable block, and sinus arrhythmia with premature atrial contractions.
AccurKardia (AccurECG Software as a Medical Device)
While Preventice Solutions, BioTelemetry, and Bardy Diagnostics vertically integrate proprietary wearable hardware with their own IDTF service bureaus, AccurKardia operates as a pure-play, device-agnostic Software as a Medical Device (SaMD) vendor. Cleared by the FDA under 510(k) K231436 (21 CFR § 870.2800 / Product Code DQK), AccurECG accepts single-lead and multi-lead ECG recordings sampled across varying frequencies from third-party Holter, event, and telemetry hardware. Its deterministic and machine-learning pipeline performs beat detection, noise/artifact segmentation, heart rate variability analysis, and automated classification across 13 rhythm categories (including sinus rhythm, atrial fibrillation/flutter, ventricular tachycardia, bigeminy, trigeminy, and heart block), outputting structured JSON/PDF reports for clinician sign-off.
How Is Preventice Solutions Used in Clinical Research and Healthcare?
In both health system electrophysiology clinics and pharmaceutical/device clinical trials, ambulatory ECG platforms must align with CMS billing rules, EHR interoperability standards, and trial endpoint adjudication protocols:
- CMS / AMA CPT Modality Selection and IDTF Billing (42 CFR § 410.33): Payers and clinical operations teams map each monitoring mode to its corresponding CPT code family (distinct from general physiologic remote patient monitoring codes such as CPT 99454 or ambulatory blood pressure monitoring):
- Short-Term Holter (up to 48 hours):
CPT 93224(global),93225(recording),93226(scanning/analysis with report), and93227(physician review and interpretation). - Extended Holter (> 48 hours up to 15 days):
CPT 93241–93244(> 48 hours up to 7 days) andCPT 93245–93248(> 7 days up to 15 days), commonly used for extended patch wear (BodyGuardian Extended Holter, Philips ePatch, Bardy CAM). - External Cardiac Event Monitoring (30-day loop memory):
CPT 93268–93272. - Mobile Cardiac Telemetry (MCT — up to 30 days):
CPT 93228(professional physician review and interpretation with report) andCPT 93229(technical support, 24-hour attended surveillance, and data transmission by a Medicare-enrolled IDTF meeting 42 CFR § 410.33 standards).
- Short-Term Holter (up to 48 hours):
- Decentralized Clinical Trials (DCTs) and Core Lab Endpoint Adjudication: In antiarrhythmic drug trials, structural heart device studies, and cardiotoxicity safety monitoring (often paired alongside sleep/activity wearables such as actigraphy), sponsors deploy BodyGuardian or MCOT kits directly to participants’ homes. Continuous MCT transmission allows Data and Safety Monitoring Boards (DSMBs) to receive immediate notifications of protocol-defined stopping criteria (e.g., sustained ventricular tachycardia, pause > 3.0 seconds, or QTc prolongation) while archiving raw continuous full-disclosure ECG waveforms for blinded core lab adjudication.
- EHR Integration (HL7 v2 ORU / FHIR DiagnosticReport): Through Preventice CareLink and cloud middleware, preliminary urgent alerts and end-of-study summary reports flow directly into the ordering health system’s EHR via HL7 v2
ORU^R01messages or HL7 FHIR R4DiagnosticReportandObservationresources, attaching discrete heart rate, AFib burden percentage, and embedded PDF rhythm strips to the patient’s chart.
Frequently Asked Questions
What is Preventice Solutions?
Preventice Solutions (acquired by Boston Scientific in 2021) is an ambulatory cardiac monitoring company and Medicare-enrolled Independent Diagnostic Testing Facility (IDTF) that develops the FDA 510(k)-cleared BodyGuardian family of wearable remote ECG monitors supporting short-term Holter, Extended Holter, Cardiac Event Monitoring, and continuous Mobile Cardiac Telemetry (MCT).
How is Preventice Solutions used in clinical research and healthcare?
In healthcare, clinicians prescribe Preventice Solutions BodyGuardian monitors to diagnose symptomatic and asymptomatic cardiac arrhythmias, evaluate syncope, and detect occult atrial fibrillation after cryptogenic stroke under CPT codes 93224–93229 and 93241–93248. In clinical research, trial sponsors use BodyGuardian and peer platforms (BioTelemetry MCOT, Bardy Diagnostics CAM, and AccurKardia SaMD) for decentralized home deployment, real-time DSMB safety alerting, and continuous AFib burden endpoint adjudication.
Sources
- U.S. Food and Drug Administration (FDA) — 510(k) Premarket Notification Database: Preventice Solutions / Boston Scientific BodyGuardian Remote Monitoring System (K121197, K192732, K243349): https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K192732
- U.S. Food and Drug Administration (FDA) — 510(k) Premarket Notification Database: AccurKardia AccurECG Analysis Software (K231436) and Bardy Diagnostics CAM Patch: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K231436
- Electronic Code of Federal Regulations (eCFR) — 42 CFR § 410.33 (Independent Diagnostic Testing Facility Performance Standards) & 21 CFR § 870.1025 / § 870.2800: https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-410/subpart-B/section-410.33
